FASLG and prostate carcinoma: Published studies have shown that apoptosis through the activation of several caspases by chemotherapy using ADM did not depend on Fas–FasL interaction in other cancers (Gamen et al, 1997; Landowski et al, 1999), among them ADM downregulated FLIP, an antiapoptotic downstream molecule of Fas, in prostate cancer cell lines, which lead to sensitise cancer cells to death receptor-mediated apoptosis (Kelly et al, 2002).